"10.1371_journal.pone.0022849","plos one","2011-09-19T00:00:00Z","Tilda Barliya; Mathilda Mandel; Tami Livnat; Dov Weinberger; Gad Lavie","The Blood Center, Sheba Medical Center, Ramat-Gan, Israel; Department of Ophthalmology, Beilinson Medical Center, Petah-Tiqva, Israel; Institute of Hematology, Sheba Medical Center, Ramat-Gan, Israel; Department of Ophthalmology, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Department of Cellular and Developmental Biology, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel","Conceived and designed the experiments: GL DW MM. Performed the experiments: TB TL. Analyzed the data: TB GL TL DW. Contributed reagents/materials/analysis tools: GL TL. Wrote the paper: GL MM.","Dr. G. Lavie has financial interest in the Hy Biopharma Corporation, which develops the drug hypericin (described here) as an anti-cancer agent. However, the company is in advanced clinical trials and is unlikely to gain anything from this publication. The research was not funded by this company and there are no other remunerations to any of the authors. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.","2011","09","Tilda Barliya","TB",5,TRUE,3,2,4,2,TRUE,TRUE,FALSE,0,NA,FALSE
